The GLP-1 revolution has reshaped biopharma M&A strategy. With Novo Nordisk and Eli Lilly generating tens of billions in annual obesity drug revenue, large-cap acquirers are scouring the biotech landscape for the…
Wall Street analysts are placing aggressive bets on four clinical-stage biotech companies, with consensus price targets implying gains of up to 384%. These pre-revenue or early-revenue firms carry significant risk, but their…
Albemarle (NYSE: ALB | ALB Price Prediction) had an incredible year. Since bottoming out at around $50 in April, the lithium giant exploded to $145.38. This morning, it’s up another $4.15 and…
The GLP-1 drug market has surged dramatically in the past four years, driven by soaring demand for weight-loss treatments that also tackle related conditions like diabetes and heart disease. Valued at over…
Short interest is always a sign of how bearish investors may be on a stock. But it can also serve as a potential sign of a coming short squeeze, especially if the…
High short interest can help investors identify potential high risks. And, it can also be a sign of a possible short squeeze situation – especially if the stock in question has been…
A Fierce Battle for Weight-Loss Supremacy The weight-loss drug market has become a battleground, ignited by the runaway success of Novo Nordisk’s (NYSE:NVO | NVO Price Prediction) Ozempic and Wegovy. These injectable…
A Comeback Fueled by Resilience Danish pharmaceutical giant Novo Nordisk (NYSE:NVO | NVO Price Prediction) has been a trailblazer in the GLP-1 drug market, revolutionizing diabetes and obesity treatment with its blockbuster…
Live Updates Tuesday Wrap-up4:12pm ETThe Vanguard S&P 500 ETF closed at 588.15 Tuesday, down 0.5%. Softbank Rides to Intel's Rescue12:10pm ET“Great minds think alike,” goes the old saying, and today, one of…
Eli Lilly (NYSE:LLY | LLY Price Prediction) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 trillion stock and the first healthcare…
Market pullbacks can make nervous investors leery of investing in industries that are more speculative. Wall Street still has big expectations for Viking Therapeutics.
Palantir Technologies (NASDAQ:PLTR | PLTR Price Prediction) has been described as the best pure-play stock in artificial intelligence. The market agrees, sending shares of PLTR stock some 342% higher over the past…
Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli Lilly (NYSE:LLY | LLY Price Prediction) has become the industry leader in a…
Jim Cramer is probably the closest thing we have to stock market superstar influencer. The host of CNBC’s “Mad Money” show is entertaining and popular with a broad swath of investors who…
Some of the best opportunities can still be found in obesity treatment stocks. Look at Viking Therapeutics (NASDAQ:VKTX | VKTX Price Prediction), for example. Now trading at $57.80, we strongly believe it…
